|
|||||
|
|
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) |
|
| Authors: | Theo de Witte Stefan Suciu Liv Meert Constantijn Halkes Dominik Selleslag Dominique Bron Sergio Amadori Roel Willemze Petra Muus Frédéric Baron |
| Institution: | 1. Radboud University Medical Centre, Nijmegen, The Netherlands 8. Department of Tumorimmunology, Radboud Institute of Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands 2. EORTC Headquarters, Brussels, Belgium 3. Leiden University Medical Center, Leiden, The Netherlands 4. St Jan’s Hospital, Brugge, Belgium 5. Institut J. Bordet (ULB), Brussels, Belgium 6. Tor Vergata University Hospital, Rome, Italy 7. University of Liege, Liege, Belgium |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |